Why Attend?

ADCs are a growing and complex class of therapeutics that present unique challenges but offer incredible patient benefits. Bioconjugation is a critical element in developing ADCs and other targeting and delivery agents.

Early assessment of bioconjugation technology options, as well as de-risking the payload, linker, and biologics targeting molecule, is crucial to optimizing the path to first-in-human studies.

If you are working on an ADC, monoclonal antibody, bispecific, or small molecule (especially in the oncology field), this talk will highlight how Lonza can partner with you from molecule design all the way through de-risking and development to clinical manufacture.

Lonza’s integrated approach and depth of expertise offer you unique advantages and real timeline optimization:

• Discover early phase drug development strategies, and discuss your project in 1:1 meetings with the speakers.
• Connect in person with industry leaders and peers in ADC and bioconjugate therapeutics.
• Learn from real-world examples: startup stories of overcoming challenges in drug development.